TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of “Moderate Buy” from Analysts

TuHURA Biosciences, Inc. (NASDAQ:HURA) has earned a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $9.00.

HURA has been the topic of a number of research reports. Citizens Jmp began coverage on TuHURA Biosciences in a report on Monday, April 27th. They issued a “market outperform” rating and a $9.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Friday, July 17th. Wall Street Zen cut shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Citigroup initiated coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued an “outperform” rating for the company. Finally, Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a research report on Wednesday, April 15th. They set a “buy” rating on the stock.

TuHURA Biosciences Stock Down 4.0%

Shares of TuHURA Biosciences stock opened at $2.15 on Friday. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $3.90. The company has a market capitalization of $136.92 million, a P/E ratio of -3.52 and a beta of -0.05. The company has a 50 day moving average of $2.33 and a 200 day moving average of $1.84.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). As a group, research analysts anticipate that TuHURA Biosciences will post -0.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TuHURA Biosciences

Hedge funds have recently modified their holdings of the company. Virtu Financial LLC bought a new position in TuHURA Biosciences in the third quarter valued at about $26,000. JPMorgan Chase & Co. bought a new stake in shares of TuHURA Biosciences during the second quarter worth about $27,000. Invesco Ltd. bought a new position in TuHURA Biosciences in the second quarter worth approximately $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of TuHURA Biosciences in the second quarter valued at about $31,000. Finally, Bank of America Corp DE bought a new position in TuHURA Biosciences in the 4th quarter worth $59,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.